Open AccessP666: ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORAMBUCIL IN TREATMENT‐NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA: 5‐YEAR FOLLOW‐UP OF ELEVATE‐TN
Author(s) -
Sharman J. P.,
Egyed M.,
Jurczak W.,
Skarbnik A.,
Patel K.,
Flinn I. W.,
Kamdar M.,
Munir T.,
Walewska R.,
Fogliatto L. M.,
Herishanu Y.,
Banerji V.,
Follows G.,
Walker P.,
Karlsson K.,
Ghia P.,
Janssens A.,
Cymbalista F.,
Ferrant E.,
Wierda W. G.,
Munugalavadla V.,
Yu T.,
Wang M. H.,
Woyach J. A.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845548.49291.01
Subject(s) - chlorambucil , obinutuzumab , ighv@ , medicine , chronic lymphocytic leukemia , gastroenterology , hazard ratio , oncology , chemotherapy , leukemia , confidence interval , cyclophosphamide